- Center on Health Equity & Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
Stuck in Prior Auth Purgatory: The Hidden Costs of Health Care Delays
Delays, denials, and endless paperwork—prior authorization isn’t just a headache for providers; it’s a barrier for patients who need timely care, explains Colin Banas, MD, MHA, chief medical officer with DrFirst.
Today, we’re diving into the frustrating world of prior authorizations. Delays, denials, and endless paperwork—this process isn’t just a headache for providers; it’s a barrier for patients who need timely care.
Joining us is Colin Banas, MD, MHA, chief medical officer at DrFirst, who willl unpack why this system is broken and how we can fix it. From shocking patient delays to the surprising role of fax machines in 2025, we’ll explore why prior auths are driving burnout, potentially harming outcomes, and what’s being done to streamline the process.
Whether you’re a provider, patient, or just curious about health care’s hidden hurdles—stick around. This is one episode you won’t want to miss.
Listen above or on one of these podcast services:
ACA Network Regulatory Filings Are Inaccurate, Poorly Match Provider Directories
September 16th 2025A secret shopper survey (N = 8306) in Pennsylvania’s Affordable Care Act (ACA) Marketplace found inconsistencies between carrier regulatory filings and provider directories, frequent inaccuracies in regulatory filings, and challenges in securing timely appointments.
Read More
Impact of Amivantamab-Lazertinib on EGFR, MET Resistance Alterations in NSCLC: Danny Nguyen, MD
September 15th 2025The combination of amivantamab and lazertinib in first-line non–small cell lung cancer (NSCLC) significantly reduces resistance mechanisms with implications for second-line treatment, said Danny Nguyen, MD, of City of Hope.
Read More
ACA Network Regulatory Filings Are Inaccurate, Poorly Match Provider Directories
September 16th 2025A secret shopper survey (N = 8306) in Pennsylvania’s Affordable Care Act (ACA) Marketplace found inconsistencies between carrier regulatory filings and provider directories, frequent inaccuracies in regulatory filings, and challenges in securing timely appointments.
Read More
Impact of Amivantamab-Lazertinib on EGFR, MET Resistance Alterations in NSCLC: Danny Nguyen, MD
September 15th 2025The combination of amivantamab and lazertinib in first-line non–small cell lung cancer (NSCLC) significantly reduces resistance mechanisms with implications for second-line treatment, said Danny Nguyen, MD, of City of Hope.
Read More
2 Commerce Drive
Cranbury, NJ 08512
AJMC®
All rights reserved.